Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-11-08
2005-11-08
Campell, Bruce R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600
Reexamination Certificate
active
06962900
ABSTRACT:
A pharmaceutical being used for treating HIV infection is provided which has the following peptide sequence: X-SWETWEREIENYTKQIYKILEESQQDRN-EKDRNEKDLLE-Z, where S is Serine, W is Trytophan, E is Glutamate, T is Threonine, R is Argine, I is Isoleucine, N is Asparagine, Y is Tyrosine, K is Lysine, Q is Glutamine, L is Leucine, D is Aspartic acid, X is amino group, acetyl-hydrophobic group, or macromolecule carrier group, Z is carboxyl group, amino group, amido group, tert-nutyloxycarbonyl group, hydrophobic group, or macromolecule carrier group. The drug inhibits strongly the infection of HIV.
REFERENCES:
Burger et al “ Evolution of Human Immunodeficiency Virus Type 1 Nucleotide Sequence Diversity Among Close Contacts,” Proc. Natl. Acad. Sci. USA, 1991, vol. 88, pp. 11236-11240.
Vella, S. et al. “HIV Resistance to Antiretroviral Drugs”International AIDS Society USA, pp. 15-18, vol. 4, No. 3.
WHO Report 1996 (copies unavailable).
“AIDS Epidemic Update: Dec. 2000”, WHO Report 2000, UNAIDS and WHO.
Zho, G. et al. “The Structure of an HIV-1 Specific Cell Entry Inhibitor in Complex with theHIV-1 gp41 Trimeric Core”,Bio. Med. Chem., 2000, pp. 2219-2228, vol. 8.
Carpenter, C. J. C. et al. “Antiretroviral Therapy for HIV Infection in 1996” JAMA, Jul. 10, 1996, pp. 146-154, vol. 276, No. 2.
Condra, J. H. et al. “In Vivo Emergence of HIV-1 Variants Resistant to Multiple Protease Inhibitors”Nature, Apr. 6, 1995, pp. 569-571, vol. 374.
Dalgleish, A. et al. “The CD4 (T4) Antigen is an Essential Component of the Receptor for the AIDS Retrovirus”,Nature, Dec. 1984, pp. 763-767, vol. 312.
Deeks, S. G. et al. “HIV-1 Protease Inhibitors: A Review for Clinicians”,JAMA, Jan. 8, 1997, pp. 145-153, vol. 277, No. 2.
Fischl, M. A. et al. “The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex. A Double-Blind, Placebo-Controlled Trial”N. Engl. J. Med., Jul. 23, 1987, pp. 185-191, vol. 317, No. 4.
Jiang, S. et al. “HIV-1 Inhibition by a Peptide”Nature, 1993, p. 113, vol. 365, No. 6442.
Lafeuillade A. et al. “Effects of a Combination of Zidovudine, Didanosine, and Lamivudine on Primary Human Immunodeficiency Virus Type 1 Infection”,J. Infect. Dis., 1997, pp. 1051-1055, vol. 175, No. 5.
Levy, J. A. (1988) Can an AIDS Vaccine be Developed?Transfus. Med. Rev. 2(4):264-271. (copies unavailable).
Levy, J. A. (2000) Acute HIV Infection and Susceptible Cells. 63-78. (copies unavailable).
Maddon, P. J. “The T4 Gene Encodes the AIDS Virus Receptor and is Expressed in the Immune System and the Brain”,Cell, 1986, pp. 333-348, vol. 47, No. 3.
Miles, S. A. et al. “Protease Inhibitors”,International AIDS Society USA, pp. 7-9, vol. 4, No. 3.
Myers, G. et al. “Evolutionary Potential of Complex Retroviruses”,The Retroviridae, vol. 1, 1992, Jay A. Levy (ed.), Plenum Press, New York.
Kilby, J. M. et al. “Potent Suppression of HIV-1 Replication in Humans by T-20, A Peptide Inhibitor of gp41-Mediated Virus Entry”,Nature Medicine, Nov. 1998, pp. 1302-1307 , vol. 4, No. 11.
Zsuzsanna, K-L. et al. “Pararetro- and retrovirus RNA: Splicing and the Control of Nuclear Export”,Trends in Microbiol., Dec. 1996, pp. 480-485, vol. 4, No. 12.
Kliger, Y. et al. “Inhibition of HIV-1 Entry Before gp41 Folds into its Fusion-active Conformation”,J. Mol. Biol., 2000, pp. 163-168, vol. 295.
Lenderkin, W. R. et al. “ Evaluation of the Quality of Life Associated with Zidovudine Treatment in Asymptomatic Human Immunodeficiency Virus Infection”N. Eng. J. Med., Mar. 17, 1994, pp. 738-743, vol. 330.
Maurer, K. et al. “Carbonyl J Derivatives: A New Class of HIV-1 Integrase Inhibitors”,Bioorganic Chemistry, 2000, pp. 140-155, vol. 28.
Mcelrath, M. J. et al. “Human Immunodeficiency Virus Type 1 Infection Despite Prior Immunization with a Recombinant Envelope Vaccine Regiment”,Proc. Natl. Acad. Sci. USA, Apr. 1996, pp. 3972-3977, vol. 93.
Pilcher, C. D. et al. “Prolonged Therapy with the Fusion Inhibitor T-20 in Combination with Oral Antiretroviral Agents in a HIV-infected Individual”,AIDS, Oct. 22, 1999, p. 2171, vol. 13, No. 15.
Roe, T. et al. “3′-End Processing and Kinetics of 5′-End Joining during Retroviral Integration in Vivo”,J. Virology, Feb. 1997, pp. 1334-1340, vol. 71, No. 2.
Weissenhorn, W. et al. “Atomic Structure of the Ectodomain from HIV-1 gp41”,Nature, May 1997, pp. 426-430, vol. 387.
White, J. M. “Membrane Fusion”Science, Nov. 6, 1992, pp. 917924, vol. 258.
Wild, C. T. et al. “Peptides Corresponding to a Predictive α-helical Domain of Human Immunodeficiency Virus Type 1 gp41 are Potent Inhibitors of Virus Infection”Proc. Natl. Acad. Sci. USA, Oct. 1994, pp. 9770-9774, vol. 91.
Xiang, Y. et al. “Altered Rous Sarcoma Virus Gag Polyprotein Processing and Its Effects on Particle Formation”,J. Virol., Mar. 1997, pp. 2083-2091, vol. 71, No. 3.
Yu, E. S. H. et al. “HIV Infection and AIDS in China, 1985 through 1994”,Amer. J. Pub. Health, Aug. 1996, pp. 1116-1122.
Tremlay, C. L. et al “Strong in Vitro Synergy Between the Fusion Inhibitor T-20 and the CXCR4 Blocker AMD-3100”JAIDS, 2000, pp. 99-102, vol. 25.
Baba, M. et al. “Mechanism of Inhibitory Effect of Dextran Sulfate and Heparin on Replication of Human Immunodeficiency Virus In Vitro”,Proc. Natl. Acad. Sci. USA, Aug. 1988, pp. 6132-6136, vol. 85.
Barré-Sinoussi, F. et al. “Isolation of a T-Lymphotroic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)”,Science, May 20, 1983, pp. 868-871, vol. 220.
Berger, E. A. et al. “Chemokine Receptors as HIV-1 Coreceptors: Roles in Viral Entry, Tropism, and Disease”,Annu. Rev. Immunol., 1999, pp. 657-700, vol. 17.
Bloom, B. R. “A Perspective on AIDS Vaccines”,Science, Jun. 28, 1996, pp. 1888-1890, vol. 272.
Chan, D. C. et al. “Core Structure of gp41 from the HIV Envelope Glycoprotein”,Cell, Apr. 18, 1997, pp. 263-273, vol. 89.
Clavel, F. et al. “Isolation of a New Human Retrovirus from West African Patients with AIDS”,Science, Jul. 18, 1986, pp. 343-346, vol. 233.
Clercq, E. D. Novel Compounds in Precilinical/Early Clinical Development for the Treatment of HIV Infections,Rev. Med. Virol., 2000, pp. 255-277, vol. 10.
Ferrer, M. et al. “Selection of gp41-Mediated HIV-1 Cell Entry Inhibitors from Biased Combinatorial Libraries of Non-Natural Binding Elements”,Nature Structural Biology, 1999, pp. 953-960, vol. 6, No. 10.
Gallo, R. C. et al. “Frequent Detection and Isolation of Cytopathic Retroviruses(HTLV-III) from Patients with AIDS and at Risk for AIDS”,Science, May 4, 1984, pp. 500-503, vol. 224.
Gomatos, P. J. et al. “Relative Inefficiency of Soluble Recombinant CD4 for Inhibition of Infection by Monocyte-Tropic HIV in Monocytes and T Cells”,J. Immunology, 1990, pp. 4183-4188, vol. 144, No. 11.
Jonassen, T. O. et al. “Sequence Analysis of HIV-1 Group O from Norwegian Patients Infected in the 1960s”,Virology, 1997, pp. 43-47, vol. 231.
Jones, P. L. St. J. et al. “Conformational Changes in Cell Surface HIV-1 Envelope Glycoproteins are Triggered by Cooperation Between Cell Surface CD4 and Co-receptors”,J. Bio. Chem., Jan. 2, 1998, pp. 404-409, vol. 273, No. 1.
Tian Wangni
Zhou Genfa
Campell Bruce R.
Heard Thomas S.
Saliwanchik Lloyd & Saliwanchik
Tianjin Fusogen Biotech Co., Ltd.
LandOfFree
Pharmaceutical being used for treating HIV infection, the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical being used for treating HIV infection, the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical being used for treating HIV infection, the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3501079